НовостиBenzingaGyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $109.500M Est Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $109.500M Est Benzinga 2026.11.05 22:30 (GMT+0) Открыть на Benzinga Другие новости